Our Global Commercial Operations


Neopharma Japan

alt textAnticipating the need for new molecules and novel therapy areas, Neopharma Japan was established in October 2016, as a subsidiary of Neopharma to enable development, manufacturing and marketing of 5 – ALA based products.

Neopharma Japan’s facilities include a manufacturing facility, NeoALA Japan, in Fukuroi. Acquired from CosmoALA Japan, in 2016, NeoALA Japan focuses on R&D and manufacturing of 5 – ALA based products.

Click here to know more about Neopharma Japan

Kyowa Criticare (Acquired by Neopharma)

Neopharma through its Japanese subsidiary neoALA Co. Ltd. Japan acquired the Japanese injectable business and related assets belonging to Kyowa (Kyowa Pharmaceutical Industry Co. Ltd.), subsidiary of Lupin Limited. The plant and associated facilities are based out of Atsugi, Japan and would be engaged in the manufacturing and commercialization of injectable products in the critical care segment.

Joint Ventures


alt textEstablished in 2008, Neobiocon FZ is a 50 - 50 joint venture between Neopharma and Biocon to manufacture and market biopharmaceuticals and in – license products.

Nexgen Pharma

alt textIn 2012, as a part of its portfolio expansion, Neopharma entered into a manufacturing and marketing joint venture with Hetero Drugs.

Alliances and Partners

Neopharma is currently working with several international pharmaceutical giants. With product licensing from Pfizer, USA and Merck KGaA and many other internationally renowned pharmaceutical companies, Neopharma offers quality medicines at affordable prices.

  • Glenmark
  • Merck Serono (Germany)
  • Hetero (India)
  • Biocon (India)
  • Lagap (Switzerland)

  • TOP